Genetic alterations of histone lysine methyltransferases and their significance in breast cancer

Similar documents
Supplementary Figure 1: High-throughput profiling of survival after exposure to - radiation. (a) Cells were plated in at least 7 wells in a 384-well

Plasma-Seq conducted with blood from male individuals without cancer.

Session 4 Rebecca Poulos

Supplementary Figure 1: Comparison of acgh-based and expression-based CNA analysis of tumors from breast cancer GEMMs.

Session 4 Rebecca Poulos

Cancer Informatics Lecture

Hands-On Ten The BRCA1 Gene and Protein

Nature Genetics: doi: /ng Supplementary Figure 1. Somatic coding mutations identified by WES/WGS for 83 ATL cases.

The Cancer Genome Atlas & International Cancer Genome Consortium

OncoPPi Portal A Cancer Protein Interaction Network to Inform Therapeutic Strategies

RNA preparation from extracted paraffin cores:

p.r623c p.p976l p.d2847fs p.t2671 p.d2847fs p.r2922w p.r2370h p.c1201y p.a868v p.s952* RING_C BP PHD Cbp HAT_KAT11

Computer Science, Biology, and Biomedical Informatics (CoSBBI) Outline. Molecular Biology of Cancer AND. Goals/Expectations. David Boone 7/1/2015

The 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis

S1 Appendix: Figs A G and Table A. b Normal Generalized Fraction 0.075

Introduction to LOH and Allele Specific Copy Number User Forum

Supplementary Figure 1. Copy Number Alterations TP53 Mutation Type. C-class TP53 WT. TP53 mut. Nature Genetics: doi: /ng.

Contents. 1.5 GOPredict is robust to changes in study sets... 5

Discovery Dataset. PD Liver Luminal B/ Her-2+ Letrozole. PD Supraclavicular Lymph node. PD Supraclavicular Lymph node Luminal B.

Package xseq. R topics documented: September 11, 2015

Expanded View Figures

Supplementary Figure 1

of TERT, MLL4, CCNE1, SENP5, and ROCK1 on tumor development were discussed.

Nature Genetics: doi: /ng Supplementary Figure 1. SEER data for male and female cancer incidence from

underlying metastasis and recurrence in HNSCC, we analyzed two groups of patients. The

Relationship between genomic features and distributions of RS1 and RS3 rearrangements in breast cancer genomes.

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer

DNA-seq Bioinformatics Analysis: Copy Number Variation

Nature Genetics: doi: /ng Supplementary Figure 1. HOX fusions enhance self-renewal capacity.

Case Studies on High Throughput Gene Expression Data Kun Huang, PhD Raghu Machiraju, PhD

Genomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France

Detection of aneuploidy in a single cell using the Ion ReproSeq PGS View Kit

Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value

Comparison of open chromatin regions between dentate granule cells and other tissues and neural cell types.

Transcriptional Profiles from Paired Normal Samples Offer Complementary Information on Cancer Patient Survival -- Evidence from TCGA Pan-Cancer Data

Supplemental Information. Molecular, Pathological, Radiological, and Immune. Profiling of Non-brainstem Pediatric High-Grade

10/15/2012. Biologic Subtypes of TNBC. Topics. Topics. Histopathology Molecular pathology Clinical relevance

Mutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research

Supplementary Tables. Supplementary Figures

HALLA KABAT * Outreach Program, mircore, 2929 Plymouth Rd. Ann Arbor, MI 48105, USA LEO TUNKLE *

Nature Genetics: doi: /ng Supplementary Figure 1

Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer

Molecular And Genetic Properties Of Breast Cancer Associated With Local Immune Activity

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

The Biology and Genetics of Cells and Organisms The Biology of Cancer

Supplementary Figures

NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation

Interactive analysis and quality assessment of single-cell copy-number variations

MolEcular Taxonomy of BReast cancer International Consortium (METABRIC)

Introduction. Introduction

Abstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction

Nature Medicine: doi: /nm.3967

Supplementary Data for:

Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser

Journal: Nature Methods

Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer

Understanding DNA Copy Number Data

Breast cancer. Risk factors you cannot change include: Treatment Plan Selection. Inferring Transcriptional Module from Breast Cancer Profile Data

The Loss of Heterozygosity (LOH) Algorithm in Genotyping Console 2.0

MammaPrint, the story of the 70-gene profile

Characterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser

AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits

Module 3: Pathway and Drug Development

Gene expression profiling predicts clinical outcome of prostate cancer. Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M.

Translational Bioinformatics: Connecting Genes with Drugs

Molecular Subtyping of Endometrial Cancer: A ProMisE ing Change

Nature Genetics: doi: /ng Supplementary Figure 1. Mutational signatures in BCC compared to melanoma.

ncounter Assay Automated Process Immobilize and align reporter for image collecting and barcode counting ncounter Prep Station

SUPPLEMENTARY FIGURE LEGENDS

Recent advances in breast cancers

The Tail Rank Test. Kevin R. Coombes. July 20, Performing the Tail Rank Test Which genes are significant?... 3

Nature Genetics: doi: /ng Supplementary Figure 1. Workflow of CDR3 sequence assembly from RNA-seq data.

Breast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)

Supplementary Online Content

Tratamiento neoadyuvante: Enfermedad residual como marcador de resistencia Carlos L. Arteaga, MD Vanderbilt-Ingram Cancer Center Vanderbilt

Breast cancer classification: beyond the intrinsic molecular subtypes

Detection of low-frequent mitochondrial DNA variants using SMRT sequencing

Contemporary Classification of Breast Cancer

Integrated Analysis of Copy Number and Gene Expression

Nature Methods: doi: /nmeth.3115

Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity

Expert-guided Visual Exploration (EVE) for patient stratification. Hamid Bolouri, Lue-Ping Zhao, Eric C. Holland

Concordance among Gene-Expression Based Predictors for Breast Cancer

Supplementary Information Titles Journal: Nature Medicine

Supplementary Figures

SSM signature genes are highly expressed in residual scar tissues after preoperative radiotherapy of rectal cancer.

Supplementary Figure 1. Spitzoid Melanoma with PPFIBP1-MET fusion. (a) Histopathology (4x) shows a domed papule with melanocytes extending into the

Supplementary Appendix

Predicting outcome in metastatic breast cancer

Table S2. Expression of PRMT7 in clinical breast carcinoma samples

Low ds/dn Does Not Correlate With High Variation of Amino Acid Sequences Along the gp120 Protein Structure

SUPPLEMENTARY APPENDIX

Myeloma Genetics what do we know and where are we going?

Cancer Gene Panels. Dr. Andreas Scherer. Dr. Andreas Scherer President and CEO Golden Helix, Inc. Twitter: andreasscherer

On the Reproducibility of TCGA Ovarian Cancer MicroRNA Profiles

Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics, 2010

Phylogenetic Methods

Numerous hypothesis tests were performed in this study. To reduce the false positive due to

An Integrated Approach to Uncover Drivers of Cancer

Transcription:

Genetic alterations of histone lysine methyltransferases and their significance in breast cancer Supplementary Materials and Methods Phylogenetic tree of the HMT superfamily The phylogeny outlined in the tree is derived from a CLUSTALW multiple sequence alignment of the full-length sequence of the default Swiss-Prot variant (HMT genes). The CLUSTALW uses a progressive alignment algorithmic approach, which entails calculating pairwise sequence alignment scores between all the proteins being aligned and then beginning the alignment with the two closest sequences and progressively adding more sequences to the alignment. GISTIC algorithm In cbioportal, the Genomic Identification of Significant Targets in Cancer (GISTIC) algorithm was used to determine the copy number status of each gene in each sample [1, 2]. The GISTIC takes segmented copy number ratios as input, separates chromosome arm-level events from focal events, and then performs two tests: (i) it identifies significantly amplified/deleted chromosome arms; and (ii) it identifies regions that are significantly focally amplified or deleted. Each aberration is assigned a G-score that considers the amplitude of the aberration as well as the frequency of its occurrence across samples. False-discovery rate q-values are then calculated for the aberrant regions, and regions with q-values below a user-defined threshold are considered significant. The putative copy number level is obtained by applying both low- and high-level thresholds to the gene copy levels of all the samples. The entries with value +/- 2 exceed the high-level thresholds for amplifications/deletions, and those with +/- 1 exceed the low-level thresholds but not the high-level thresholds. Multivariate survival analysis A Cox proportional hazard model was used for multivariate analysis, and hazard ratio (HR) was calculated according to the cut-off value of a 95% confidence interval (CI). For 468 TCGA breast cancer samples, factors included in the multivariate analysis model were age at diagnosis, ER status (positive vs. negative), PR status (positive vs. negative), HER2 status (positive vs.

negative), tumor size (>20 mm vs. 20mm), lymph node status (positive vs. negative), metastasis status (positive vs. negative), and PAM50 subtype (basal vs. non-basal). To investigate DNA copy number associated with survival, samples were segregated into the following three groups for each HMT: amp/gain (high-level amplification and low-level gain), diploid, or deletion (heterozygous and homozygous deletion). Of the altered samples, fewer than 30 were excluded from this analysis in order to prevent skewed data resulting from small sample sizes. To analyze the relationships between HMT mrna expression and overall patient survival in breast cancer, samples were divided into low (n=385) and high (n=385) groups based on mrna expression Z- scores [RNA-Seq V2 RSEM (RNA-Seq by Expectation-Maximization)] of each HMT. Multivariate survival analysis was conducted using the Cox regression function ( coxph ) in the R statistical programming language.

Figure S1: Phylogenetic analysis of histone lysine methyltransferases. The image was obtained from the ChromoHub database (http://www.thesgc.org). The phylogeny outlined in the tree is derived from a CLUSTALW multiple sequence alignment of the full-length sequence of the default Swiss-Prot variant. One HMT, DOT1L, which does not contain a SET domain, was not shown.

Figure S2: CNAs of eight HMTs in 17 breast cancer cell lines. DNA copy number alterations (CNAs) for eight selected HMTs in breast cancer cell lines from comparative genomic hybridization analysis and the TCGA database. Basal-like cell lines are highlighted in red, HER2+ in green, and Luminal in blue. Values represent homozygous deletion (-2), heterozygous loss (-1), diploid (0), low-level gain (+1), and high-level amplification (+2). Deletion/loss is colored in green, and gain/amplification is in red.

Figure S3: mrna expression levels from RNA-Seq (GSE48216) of eight HMTs in a panel of 42 breast cancer cell lines compared with 5 normal mammary epithelial cell lines. Cell line names: black indicates normal mammary epithelial cell lines; red, basal-like breast cancer cell lines; green, HER2+ breast cancer cell lines; and blue, Luminal breast cancer cell lines.

Figure S4: Overall survival associated with KMT2C mutation in breast cancer (Log-rank test p- value = 0.26). Figure S5: (A) Homozygous deletion of SETDB2 and RB1 at 13q14, and (B) high-level amplification of WHSC1L1 and other 8p11-12 genes (ZNF703, ERLIN2, RAB11FIP1, LSM1, BAG4, FGFR1, and C8ORF4) in the TCGA breast cancer dataset (n=958). Data are displayed using the Oncoprint tool from cbioportal.

References 1. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R and Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copynumber alteration in human cancers. Genome Biol. 2011; 12(4):R41. 2. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, Perner S, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007; 104(50):20007-20012.